List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number

Size: px
Start display at page:

Download "List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number"

Transcription

1 Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments. Breast Cardiac Biomarker (Cabot) CABOT Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy Breast IND.197 A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer (IND197) Breast IND.213 A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer NCT NCT Breast LEGACY Establishment of a cohort of girls in breast cancer families The Ontario LEGACY Pilot Breast MA.33 A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (Dcis) Of The Breast Breast MA.34 (BIG 4-11 / BO25126 / TOC4939g) Aphinity A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as dj t th i ti t ith NCT NCT Page 1 of 11

2 Breast MAC.15 (S1007) A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor- Positive and Her2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less NCT Breast Once-A-Day Partial OPAR 5D CRT randomized to 27.5 vs 30 GY Breast Irradiation(OPAR) Breast ONCOTYPE DX A Prospective Cohort Study to Evaluate the Oncotype DX Test in Early Stage Breast Cancer GI CO.21 CHALLENGE A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) GI CRC.6 A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer GI IND.210 A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer NCT NCT NCT NCT Page 2 of 11

3 GI PA.6 (PRODIGE) Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mfolfirinox) in Patients With Resected Pancreatic Adenocarcinoma NCT GU\RENAL 9785-CL-0401 MDV 3100 EAP Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel- Based Chemotherapy NCT GU\RENAL AV A Rollover Protocol to Allow Continued Access to Tivozanib (AV-951) for Subjects Enrolled in Other Tivozanib Protocols GU\RENAL CFG920X2101 A phase I/II, multicenter, open-label dose finding study of oral CFG920 in patients with metastatic castration-resistant prostate cancer GU\RENAL IMRT_ISD_JARES Randomized Study of Quality of Life in Patients with High-Risk Prostate Cancer Undergoing Radiotherapy: Role of Pelvic Nodal IMRT GU\RENAL IND.205 A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer NCT NCT NCT GU\RENAL MUC1 MUC1/CAN-ON- 001 A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 NCT Page 3 of 11

4 GU\RENAL OGX AFFINITY A randomized phase 3 study comparing cabazitaxel/prednisone in combination with custirsen (OGX-011) to cabazitaxel/prednisone for second-line chemotherapy in men with metastatic castrate resistant prostate cancer GU\RENAL OGX A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma GU\RENAL OZM-042 A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer. GU\RENAL PR.13 PR.13(Arm A) Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) NCT NCT NCT NCT GU\RENAL RTOG 0534:Phase III PELVIC Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer NCT GU\RENAL RTOG 0938:Phase II Hypofractionated RT for prostate A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer NCT Page 4 of 11

5 GU\RENAL VEG113387(PROTECT) PROTECT A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT) GYNE CBKM120C2201 A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma On hold NCT NCT GYNE Brachytherapy-Rectal Retraction Dosimetric Comparison of Rectal Retraction Methods in Brachytherapy for Cervical Carcinoma GYNE CX.5 (SHAPE):Early Stage 1A2 and 1B1 SHAPE Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Early Stage Cervical Cancer CT GYNE INCB :biochemical recurrence only A Phase 2 Study of the IDO Inhibitor INCB Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy NCT GYNE MK :Platinum Sensitive p53 mutant A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK ) GYNE PET LACE The Impact of Positron Emission Tomography (PET) Imaging in Women With Locally Advanced Cervical Cancer NCT NCT Page 5 of 11

6 GYNE PHL-085:recurrent /metastatic HPV related PHL085 A Phase 2 Study of Ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma of either squamous cell or adenocarcinoma histologies NCT Head&Neck DOVE A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE) Head&Neck REO 018 Efficacy Study of REOLYSIN in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers Head&Neck RTOG 0631:Phase II/III Radiosurg for spine METs Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Head&Neck T2 Larynx Phase I Study of Tolerance of Localized Glottic (T2 N0) Cancer treated with Dose Escalated Intensity Modulated Radiation Therapy Hematology CAMN107A2408 (STOP) A phase II, single arm, open label study of treatment-free remission after achieving sustained MR4.5 on nilotinib Hematology IND.193 IND.193 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia. Hematology IND.194 A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma NCT NCT NCT NCT NCT NCT Page 6 of 11

7 Hematology PCI-32765CLL3001 (HELIOS) PCI-32765CLL3001 Randomized, Double-blind, Placebocontrolled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (The HELIOS trial). NCT Lung STA A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC) On hold NCT Lung CA A Multi-arm Phase I study of BMS in combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in subjects with Chemotherapy-Naive Stage IIIB/IV Nonsmall Cell Lung Cancer (NSCLC) Lung CONVERT BR.28 A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status Lung EMR Collect Long-term Data on Subjects Following Participation in Previous EMD (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials NCT NCT Page 7 of 11

8 Lung IMGN IMGN901 A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin/Etoposide in Patients with Advanced Solid Tumors including Extensive Stage Small Cell Lung Cancer NCT Lung IND.207 A Phase II Study of PF in Patients With Advanced Malignant Pleural Mesothelioma Lung IND.211 A Randomized Phase II Study Of Reolysin In Patients With Previously Treated Advanced Or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy Lung OCOG-2011-BRACHY Brachy A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy (BRACHY) NCT NCT NCT Lung STA Galaxy Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Lung TIDAL Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non- Small Cell Lung Cancer (TIDAL) NCT NCT Page 8 of 11

9 Melanoma GO28141: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB + PLACEBO VERSUS VEMURAFENIB IN COMBINATION WITH GDC-0973 IN GO28141: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VEMURAFENIB + PLACEBO VERSUS VEMURAFENIB IN COMBINATION WITH GDC-0973 IN Melanoma MEK A Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIc) or metastatic (Stage IV) BRAF V600E/K mutation-positive cutaneous melanoma. NCT Neuro CBKM120E2101 A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Neuro CDX (ACT IV) ACT IV An International, Randomized, Double- Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIIIpositive Glioblastoma (The ACT IV Study) Neuro CE.6 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme NCT NCT NCT Page 9 of 11

10 Neuro CEC.3/N107C A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease NCT Neuro GO27819 Phase II Study of MetMAb in Patients with Recurrent Glioblastoma G GO27819 a randomized, double-blind, placebo-controlled, multicenter phase ii study evaluating the efficacy and safety of onartuzumab in combination with bevacizumab or onartuzumab monotherapy in patients with recurrent glioblastoma NCT Neuro JNG-001 TRICK A Randomized Trial of Robotic Compared to Fixed Gantry Radiosurgery for Brain Metastases. Neuro N0574(RTOG 0671) Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Other (TasQ) TasQ (OZM-047) A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas Other IND.206 A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Other PROUD Study (PAL-ABST- PROUD/Abstral 401) Program Abstral Drug Utilization Study - Observational Study Evaluating "Real World" Utilization of Abstral in Canada NCT NCT NCT NCT Page 10 of 11

11 Phase I TGWS-001 Feasibility Clinical Study of Targeted and Genome-Wide Sequencing Phase I NP27872 A multi-center, open-label, first-in-human, phase I dose-escalation study of single agent RO , a small molecule MDM2 antagonist, administered orally in patients with advanced malignancies, except leukemia Phase I PJC-008 A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors with an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumor Phase I SOR-C13 01 A Phase I, Open-Label, Dose Escalation Study To Assess Safety and Tolerability of Sor-C13 in Subjects with Advanced Solid Tumors Commonly Known to Express The Trpv6 Ion Channel Sarcoma SR.6 SARC021 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma On hold NCT NCT NCT NCT NCT * You can search the trial details by putting the clnical trial gov number in the website: or search for key words at Updated May 8, 2013 Page 11 of 11

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number Breast ALTENS(Hot Flash Study) Hot Flash Study A Phase II Study of Acupuncture-like trancutaneous electrical nerve stimulation in the management of vasomotor symptoms induced by breast cancer treatments.

More information

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number

List of Actively Accruing Cancer Clinical Trials. DST Study Protocol acronym Project Title Site status detail Clinical trials gov number Breast Cardiac Biomarker (Cabot) CABOT Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy Breast IND.213 A Study of Reolysin For Patients With Advanced/Metastatic

More information

Receiving Adjuvant Trastuzumab. A randomized double-blind, placebocontrolled

Receiving Adjuvant Trastuzumab. A randomized double-blind, placebocontrolled DST Study Protocol acronym Study Title Site Status Detail Determining the Cardiac Biomarker Profile in Breast Cancer Patients Cardiac Biomarker Receiving Adjuvant Trastuzumab Breast (Cabot) CABOT Therapy

More information

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles

WASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles 2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

Page 1 of 9 printed on 06 May 2015

Page 1 of 9 printed on 06 May 2015 Sarcoma ALDOXORUBICIN-P-3-STS-01 A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator s Choice in Subjects with Metastatic,

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1

More information

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD

CLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II

More information

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD

Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating

More information

Title Cancer Drug Phase Status

Title Cancer Drug Phase Status Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer

More information

Open NCT NCT Open NCT

Open NCT NCT Open NCT Updated Feb 18/16. Please note, although every effort is made to keep this list as up-to-date as possible, some trial status updates may not be reflected in the list below. DST Project Title Project Display

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including

More information

National Cancer Drugs Fund List - Approved

National Cancer Drugs Fund List - Approved National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer

More information

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT

NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and

More information

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:

National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design: Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA

More information

All Studies by Indication

All Studies by Indication Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of

More information

CLINICAL TRIALS ACC. Jul 2016

CLINICAL TRIALS ACC. Jul 2016 CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 5: March 23, 2011 The Clinical Research E-News Now Open: CALGB 90802, Randomized Phase III trial comparing everolimus plus placebo versus everolimus plus bevacizumab for advanced renal

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination

More information

Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat

Clinical Research in Rare Cancers. Friday 10 th February Matt Seymour & Nicola Keat Clinical Research in Rare Cancers Friday 10 th February 2012 Matt Seymour & Nicola Keat Rare cancer is a common disease Rare Cancer : [prevalence

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD, Mary J. Mackenzie, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

Keytruda (pembrolizumab)

Keytruda (pembrolizumab) Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study PNH Registry M07-001 DRUG CO NCT01374360 Blood Disorders-Other PNH Registry A071102 ALLIANCE NCT02152982

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 4: March 2, 2011 The Clinical Research E-News Now Open: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study of

More information

The Clinical Research E-News

The Clinical Research E-News Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate

More information

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68

Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved

More information

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD

Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right

More information

Open clinical uro-oncology trials in Canada

Open clinical uro-oncology trials in Canada Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada ADRENOCORTICAL MALIGNANCIES CISPLATIN-BASED

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized

More information

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group

Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.

London Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list. February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Summary of Research and Writing Activities in Oncology

Summary of Research and Writing Activities in Oncology Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,

More information

I. Diagnosis of the cancer type in CUP

I. Diagnosis of the cancer type in CUP Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:

More information

Radiation Oncology MOC Study Guide

Radiation Oncology MOC Study Guide Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Etudes cliniques Service d Oncologie - Radiothérapie

Etudes cliniques Service d Oncologie - Radiothérapie Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer

More information

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship

CancerPACTS. Cancer Patients Alliance for Clinical Trials and Survivorship CancerPACTS Cancer Patients Alliance for Clinical Trials and Survivorship Listing of Cancer Clinical Trials Silicon Valley area of California Summer / Fall 2011 Solid Tumors 1. Breast. 2 2. Central Nervous

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 2: ISSUE 23: December 16, 2010 Coming soon: E1608, A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients with Advanced Melanoma E2208, Randomized Phase II Study

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 9: May 18, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: RTOG 0837, A Randomized,

More information

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling CHK1 Inhibitor Prexasertib, LY2606368 MsOH H 2 O Derived from Garrett MD and Collins I 1 ; Thompson R and Eastman A. 2 Drug Discovery Platform: Cancer Cell Signaling A Phase 2 Study of LY2606368 in Patients

More information

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication.

The Royal Marsden NHS Foundation Trust Medicines Formulary. NICE register for medicines initiated at the trust. Type and code. Publication. NICE register for medicines initiated at the trust. CG denotes Clinical Guideline TA denotes Technical Appraisal For further information about NICE and full guidelines please refer to www.nice.org.uk Title

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Studies proceeding under pre HRA-Approval system (NHS Permission)

Studies proceeding under pre HRA-Approval system (NHS Permission) 15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317 Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 2: January 26, 2011 The Clinical Research E-News Now Open: E2208, Randomized Phase II Study of Paclitaxel With or Without the Anti- IGF-IR mab Cixutumumab (IMC-A12) as Second Line Treatment

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Open Trials as of end of March 2016

Open Trials as of end of March 2016 EORTC 10085 PRO EORTC 10085 prospective part, Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG inter study 30 30-Jun-2016 estelle.cassoly@sakk.ch IBCSG

More information

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona

Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List

HSHS St. Vincent Hospital Regional Cancer Center Adult Active Study List NHLBI-MDS ECOG-A NCT02775383 Blood Disorders-Other The National Myelodysplastic Syndromes (MDS) Study A221101 ALLIANCE NCT01781468 Brain A Phase III Randomized, Double-Blind Placebo Controlled Study of

More information

Currently recruiting trials and/or near future recruitment

Currently recruiting trials and/or near future recruitment Clinical Trials at the Bank of Cyprus Oncology Centre (As of Jan 2018) Currently recruiting trials and/or near future recruitment Development of a module to supplement the EORTC Core instruments for assessment

More information

Roche setting the standards of cancer care Oncology Event for Investors, June 19

Roche setting the standards of cancer care Oncology Event for Investors, June 19 Roche setting the standards of cancer care Oncology Event for Investors, June 19 Kapil Dhingra, VP Medical Science Developing a drug to the standard of care Superior clinical benefit, resources and time

More information

NCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18

NCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18 GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,

More information

The Clinical Research E-News

The Clinical Research E-News Volume 2: ISSUE 5: March 10, 2010 The Clinical Research E-News Coming soon: AZ1071, A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative

More information

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012

SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012 SHORE HEALTH SYSTEM INSTITUTIONAL REVIEW BOARD MHE Boardroom April 10, 2012 10 IRB members 6 or more = a quorum ATTENDANCE Chairman: Robert Cattaneo, JD - non-scientist Joan Banks non-scientist Kim Billingslea,

More information

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures

2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures 2011 Physician Quality Reporting System Measures for Consideration by Oncology Providers: Cancer Care Measures The table below includes measures directly relevant to oncology providers as well as general

More information

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan

University of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials

More information

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014

Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC. NRG Semi-Annual Meeting Sunday, February 9, 2014 Research Strategy Committee Mitch Machtay, MD Deputy Group Chair, NRG RSC NRG Semi-Annual Meeting Sunday, February 9, 2014 The size of the Federal budget is not an appropriate barometer of social conscience

More information

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma

Bone Marrow Transplant Gynecologic Immunotherapy Phase 1. Breast Head & Neck Melanoma/Skin Sarcoma Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding

More information

General Information, efficacy and safety data

General Information, efficacy and safety data Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie

More information

GI ONCOLOGY CLINICAL TRIALS AT UCDAVIS

GI ONCOLOGY CLINICAL TRIALS AT UCDAVIS G ONCOLOGY CLNCAL TRALS AT UCDAVS Version: DECEMBER 2017 Please contact us with any questions or any potential clinical patients Edward Kim, MD/PhD email: jhkim@ucdavis.edu pager: 916-816-4059 May Cho,

More information

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:

SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by: ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.

More information

New Developments in Cancer Treatment. Ian Rabinowitz MD

New Developments in Cancer Treatment. Ian Rabinowitz MD New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis

More information

17 th ESO-ESMO Masterclass in clinical Oncology

17 th ESO-ESMO Masterclass in clinical Oncology 17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated

More information

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished

Target date to recruit patients agreed? Target range minimum. Target range maximum. Agreed 1 1 Agreed 01/01/ /01/2016 Recruitment Finished No REC Reference IRAS No Title Target number of patients agreed? Target range minimum Target range maximum Target date to recruit patients agreed? Planned Recruitment end date No of patients recruited

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 3: ISSUE 16: September 28, 2011 Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: C70604, A Randomized,

More information

Erbitux. Erbitux (cetuximab) Description

Erbitux. Erbitux (cetuximab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)

More information

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications

We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications We re Reaching Ludicrous Speed: New Immunotherapy Oncology Medications Adam Peele, PharmD, BCPS, BCOP Oncology Pharmacy Manager Cone Health Disclosures Merck Pharmaceuticals Speaker s Bureau 1 Objectives

More information

Dr. Andres Wiernik. Lung Cancer

Dr. Andres Wiernik. Lung Cancer Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional

More information

Update: Top Ten Cancers. David C. Dale, MD Professor of Medicine University of Washington

Update: Top Ten Cancers. David C. Dale, MD Professor of Medicine University of Washington Update: Top Ten Cancers David C. Dale, MD Professor of Medicine University of Washington Common Cancers-USA Type New Cases Deaths 1. Breast 232,000 40,000 2. Lung 221,000 158,000 3. Prostate 220,000 28,000

More information

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:

More information

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy

Carcinosarcoma Trial rial in s a in rare malign rare mali ancy Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with

More information

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017

6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

OPEN TRIALS Accruals counted until 30-April Current Accrual

OPEN TRIALS Accruals counted until 30-April Current Accrual Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine

More information

ASCO 2014 Highlights*

ASCO 2014 Highlights* ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s

More information

Best of ASTRO 2016 Czech Republic

Best of ASTRO 2016 Czech Republic Best of ASTRO 2016 Czech Republic 20. 3. 2017 Kongresové centrum Kunětická Hora Dříteč 09:30-10:10 Track 1 - Gastrointestinal Renata Soumarova, Ass. Prof. (Oncology Centre Novy Jicin, Agel) Abstract 1:

More information

What s New in Clinical Oncology? Highlights from the 2009 ASCO Annual Meeting

What s New in Clinical Oncology? Highlights from the 2009 ASCO Annual Meeting Clin Oncol Cancer Res (2009) 6: 235-240 DOI 10.1007/s11805-009-0235-3 235 What s New in Clinical Oncology? Highlights from the 2009 ASCO Annual Meeting Xiaolong Jiao Yilian Yuan ABSTRACT This review summarizes

More information

Quiz. b. 4 High grade c. 9 Unknown

Quiz. b. 4 High grade c. 9 Unknown Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm

More information

List of Available TMAs in the PRN

List of Available TMAs in the PRN TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2

More information